SCHEMBL12848993

SCHEMBL12848993

COc1cc(-c2cn3cc(F)ccc3n2)ccc1OCc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.55
SMN1; SMN2 Q16637 8/20 0.55
ALDH1A1 P00352 8/20 0.55
KDM4E B2RXH2 7/20 0.55
MAPT P10636 7/20 0.55
NPC1 O15118 6/20 0.55
HPGD P15428 5/20 0.55
HSD17B10 Q99714 5/20 0.55
TP53 P04637 2/20 0.55
PKM P14618 2/20 0.55
MAPK1 P28482 2/20 0.55
NFKB1 P19838 2/20 0.55
NFKB2 Q00653 2/20 0.55
RELA Q04206 2/20 0.55
HTT P42858 2/20 0.55
ALOX15 P16050 1/20 0.55
TSHR P16473 5/20 0.54
LMNA P02545 2/20 0.53
ADORA2A P29274 1/20 0.51
ALDH1A3 P47895 4/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12848935 0.89 ALDH1A3 (0.58) RAB9ASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL12848495 0.89 RAB9A (0.70) RAB9ASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL12797578 0.88 NPC1 (0.48) RAB9ASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL12848496 0.87 RAB9A (0.71) RAB9ASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL12848594 0.87 RAB9A (0.55) RAB9ASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL12848874 0.87 ALDH1A1 (0.52) RAB9ASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL12848491 0.86 RAB9A (0.68) RAB9ASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL6388711 0.86 RAB9A (0.74) RAB9ASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL12848995 0.85 KDM4E (0.52) RAB9ASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL6875244 0.83 HRH3 (0.62) RAB9ASMN1; SMN2ALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895599-B2 Lipoprotein lipase-activating compositions comprising benzene derivates OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2014-11-25 US disclosed
US-20130296342-A1 LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATES OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2013-11-07 US disclosed
US-20110065728-A1 LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATIVES OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130296342-A1 LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATES LPL, LIPC, LIPE RAB9A 3933/4885SMN1; SMN2 4449/4885ALDH1A1 332/4885
US-20110065728-A1 LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATIVES LPL, LIPC, LIPE RAB9A 3849/4885SMN1; SMN2 4508/4885ALDH1A1 419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.